NEJM Journal Watch Podcasts: Clinical Conversations

Podcast 299: Lung cancer and atezolizumab — results from the IMpower010 trial


Listen Later

A VIDEO RECORDING OF THIS INTERVIEW IS AVAILABLE HERE. Interim results on overall survival in phase 3 of the IMpower010 trial were presented at this year’s meeting of the International Assosciation for the Study of Lung Cancer (IASLC). As part of the NEJM Group’s coverage of the conference, Christine Sadlowski interviewed the presenter, Dr. Enriqueta Felip. […]
...more
View all episodesView all episodes
Download on the App Store

NEJM Journal Watch Podcasts: Clinical ConversationsBy NEJM Group

  • 4.5
  • 4.5
  • 4.5
  • 4.5
  • 4.5

4.5

56 ratings


More shows like NEJM Journal Watch Podcasts: Clinical Conversations

View all
JAMA Editors' Summary by JAMA Network

JAMA Editors' Summary

139 Listeners

English News - NHK WORLD RADIO JAPAN by NHK WORLD-JAPAN

English News - NHK WORLD RADIO JAPAN

429 Listeners

NEJM Interviews by NEJM Group

NEJM Interviews

126 Listeners

6 Minute English by BBC Radio

6 Minute English

1,755 Listeners

NEJM This Week by NEJM Group

NEJM This Week

322 Listeners

CHEST Journal Podcasts by American College of Chest Physicians

CHEST Journal Podcasts

63 Listeners

JAMA Clinical Reviews by JAMA Network

JAMA Clinical Reviews

502 Listeners

Mayo Clinic Talks by Mayo Clinic

Mayo Clinic Talks

282 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,333 Listeners

The Daily by The New York Times

The Daily

111,088 Listeners

Leadership Conversations by NEJM Group

Leadership Conversations

6 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,111 Listeners

Curbside Consults by NEJM Group

Curbside Consults

90 Listeners

What's That Rash? by ABC listen

What's That Rash?

248 Listeners

Febrile by Sara Dong

Febrile

187 Listeners

NEJM AI Grand Rounds by NEJM Group

NEJM AI Grand Rounds

52 Listeners

Intention to Treat by NEJM Group

Intention to Treat

32 Listeners

Not Otherwise Specified by NEJM Group

Not Otherwise Specified

45 Listeners